Tick-borne bacterial, rickettsial, spirochetal, and protozoal infectious diseases in the United States: A comprehensive review

被引:19
作者
Amsden, JR [1 ]
Warmack, S [1 ]
Gubbins, PO [1 ]
机构
[1] Univ Arkansas Med Sci, Dept Pharm Practice, Coll Pharm, Little Rock, AR 72205 USA
来源
PHARMACOTHERAPY | 2005年 / 25卷 / 02期
关键词
tick-borne disease; ehrlichiosis; Rocky Mountain spotted fever; tularemia; southern tick-associated rash illness; babesiosis; tick-borne relapsing fever; RMSF; STARI; TBRE;
D O I
10.1592/phco.25.2.191.56948
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Approximately 900 tick species exist worldwide, and they parasitize a variety of mammals, including humans; thus, ticks play a significant role in the transmission of infectious diseases. In the United States, tick-borne diseases are seasonally and geographically distributed; they typically occur during spring and summer but can occur throughout the year. Tick-borne diseases are endemic to a variety of geographic regions of the United States, depending on the species of tick commonly found in a specific locale. Specific tick-borne diseases are difficult to diagnose. Most patients have vague constitutional symptoms and nonspecific laboratory findings. Initially, serologic methods are of little benefit because they lack sensitivity early in the disease course. Therefore, a thorough history and physical examination are necessary for establishing a diagnosis. Antimicrobial regimens for tick-borne infections are poorly studied but well established. Tetracyclines and rifampin form the cornerstones of therapy for most tick-borne infections, but these agents may not be suitable for all patient populations. Therefore, no single agent can be chosen empirically to treat all tick-borne diseases. Because pharmacists are the most accessible health care providers, they are often asked how to treat tick-borne diseases. Thus, practitioners should be familiar with the ticks that inhabit their locale.
引用
收藏
页码:191 / 210
页数:20
相关论文
共 148 条
[11]   EVALUATION OF CIPROFLOXACIN AND DOXYCYCLINE IN THE TREATMENT OF MEDITERRANEAN SPOTTED-FEVER [J].
BELTRAN, RR ;
HERRERO, JIH .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1992, 11 (05) :427-431
[12]   Babesiosis [J].
Boustani, MR ;
Gelfand, JA .
CLINICAL INFECTIOUS DISEASES, 1996, 22 (04) :611-614
[13]   RECENT TRENDS IN EPIDEMIOLOGY OF TULAREMIA IN UNITED-STATES [J].
BOYCE, JM .
JOURNAL OF INFECTIOUS DISEASES, 1975, 131 (02) :197-199
[14]   TICK-BORNE RELAPSING FEVER - INTERSTATE OUTBREAK ORIGINATING AT GRAND-CANYON-NATIONAL-PARK [J].
BOYER, KM ;
MUNFORD, RS ;
MAUPIN, GO ;
PATTISON, CP ;
FOX, MD ;
BARNES, AM ;
JONES, WL ;
MAYNARD, JE .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1977, 105 (05) :469-479
[15]   Efficacy of doxycycline, azithromycin, or trovafloxacin for treatment of experimental Rocky Mountain spotted fever in dogs [J].
Breitschwerdt, EB ;
Papich, MG ;
Hegarty, BC ;
Gilger, B ;
Hancock, SI ;
Davidson, MG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (04) :813-821
[16]  
BRIGGS GG, 1998, DRUGS PREGNANCY LACT, P1011
[17]   INVITRO ANTIBIOTIC SUSCEPTIBILITY OF THE NEWLY RECOGNIZED AGENT OF EHRLICHIOSIS IN HUMANS, EHRLICHIA-CHAFFEENSIS [J].
BROUQUI, P ;
RAOULT, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (12) :2799-2803
[18]   Human granulocytic ehrlichiosis during pregnancy treated successfully with rifampin [J].
Buitrago, MI ;
Ijdo, JW ;
Rinaudo, P ;
Simon, H ;
Copel, J ;
Gadbaw, J ;
Heimer, R ;
Fikrig, E ;
Bia, FJ .
CLINICAL INFECTIOUS DISEASES, 1998, 27 (01) :213-215
[19]   Ehrlichia ewingii, A newly recognized agent of human ehrlichiosis [J].
Buller, RS ;
Arens, M ;
Hmiel, SP ;
Paddock, CD ;
Sumner, JW ;
Rikihisa, Y ;
Unver, A ;
Gaudreault-Keener, R ;
Manian, FA ;
Liddell, AM ;
Schmulewitz, N ;
Storch, GA .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (03) :148-155
[20]   IMMUNIZATION AGAINST TULAREMIA - ANALYSIS OF EFFECTIVENESS OF LIVE FRANCISELLA-TULARENSIS VACCINE IN PREVENTION OF LABORATORY-ACQUIRED TULAREMIA [J].
BURKE, DS .
JOURNAL OF INFECTIOUS DISEASES, 1977, 135 (01) :55-60